2023 World Conference on Lung Cancer (Posters)-P2.09. Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers

P2.09. Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to analyze the racial diversity and co-mutational profiles of EGFR mutant lung cancers (LCas) using real-world data from the Tempus database. The incidence and subtypes of EGFR alterations and their co-mutational status have been well described in Caucasian and East Asian populations but not in African American populations. The researchers identified de-identified records of LCa patients with a primary diagnosis of lung cancer and a pathogenic EGFR mutation. The race of the patients was determined based on clinical records and categorized as Caucasian, African American, Asian Pacific Islander, or unknown/other. The data was analyzed using statistical tests and comparisons.<br /><br />The results showed that out of 17,482 LCa samples, the majority were Caucasian (55.1%), followed by African American (7.7%), Asian Pacific Islander (2.5%), and unknown/other (31.7%). Pathogenic EGFR alterations were found in 8.9% of Caucasian patients, 7.8% of African American patients, 39.5% of Asian Pacific Islander patients, 15.1% of other patients, and 11.9% of unknown patients. The frequency of specific EGFR alterations, such as exon 19 deletions and L858R mutations, differed across racial groups. EGFR copy number variations (CNVs) were highest in African American patients. Co-mutations in genes like KMT2C and GLI1 also varied across races, with higher frequencies observed in African American patients. No significant differences were observed in T790M or exon 20 insertions. Additionally, no differences were found in TP53, RB1, or NTRK2/3 mutations.<br /><br />In conclusion, this study found significant differences in the prevalence of EGFR alterations and specific co-mutations across racial groups. These variabilities may have implications for more targeted and effective treatment strategies for patients with EGFR mutant lung cancers.

Asset Subtitle

Shirish Gadgeel

Meta Tag

Speaker Shirish Gadgeel

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

racial diversity

co-mutational profiles

EGFR mutant lung cancers

real-world data

Tempus database

incidence

subtypes

EGFR alterations

African American populations

de-identified records